MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen

Figures & data

Table I. Patient and genotype characteristics.

Characteristics	No. of patients (%)
Age at diagnosis, years
40–49	1 (1.5)
50–59	14 (21.5)
60–69	15 (23.1)
≥ 70	35 (53.8)
T stage (UICC)
1	20 (30.8)
2	33 (50.8)
3	6 (9.2)
4	6 (9.2)
Nodal status
N−	8 (12.3)
N+	57 (87.7)
Stage (UICC)
I	5 (7.7)
II	46 (70.8)
III	14 (21.5)
Treatment
TAM only	18 (27.7)
TAM/radiation	47 (72.3)
MnSOD rs4880 genotype^a
AA	18 (28.1)
AG	37 (57.8)
GG	9 (14.1)
XPD rs13181 genotype
AA	17 (26.2)
AC	35 (53.8)
CC	13 (20.0)
Vital status
Alive	13 (20.0)
No recurrence	12 (18.5)
Recurrence of breast cancer	1 (1.5)
Death	52 (80.0)
Breast cancer caused death	24 (36.9)
Death of other causes	28 (43.1)

TAM, tamoxifen; UICC, International Union Against Cancer.

^ars4880 genotype was available for 64 patients.

Figure 1. Cox proportional analysis survival curves for relapse-free survival (RFS) and breast cancer-specific survival (BCSS) subdivided according to rs4880 genotype (A and B, respectively) in 64 TAM treated patients, and RFS and BCSS according to rs13181 genotype (C and D, respectively) in 65 TAM treated patients.

Table II. MnSOD rs4880 and XPD rs13181 genotypes and survival of TAM-treated patients.

		RFS			BCSS			OS			median OS (years)
Cases	n	HR^a	95% CI	p^b	HR^a	95% CI	p^b	HR^a	95% CI	p^b
rs4880	64
GG	9	1.00^c			1.00^c			1.00^c			3.6
AA or AG	55	0.36	0.14–0.91	0.030	0.33	0.12–0.91	0.032	0.54	0.23–1.24	0.15	9.2
rs13181	65
AC or CC	48	1.00^c			1.00^c			1.00^c			7.7
AA	17	0.36	0.13–1.00	0.049	0.30	0.10–0.95	0.040	0.48	0.23–1.00	0.051	12.6

BCSS, breast cancer-specific survival; CI, confidence interval; HR, hazard ratio; OS, overall survival; RFS, relapse-free survival; TAM, tamoxifen.

^aHRs adjusted for age, stage, and radiation therapy; ^bp was based on Cox proportional analysis; ^cReference value.

Figure 2. Cox proportional analysis survival curves for relapse-free survival (RFS) (A), breast cancer-specific survival (BCSS) (B) and overall survival OS (C) in 64 TAM treated patients with 0 (dotted line) or at least 1 (solid line) low-risk rs4880 and rs13181 genotype (rs4880 AA, rs4880 AG, or rs13181 AA). Adjustments were made for age, stage, and radiation therapy.